v3.20.1
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Operating costs and expenses:    
Research and development $ 1,820 $ 3,574,855
Patent costs 3,791 48,625
General and administrative 2,209,468 1,153,577
Total operating costs and expenses 2,215,079 4,777,057
Operating loss (2,215,079) (4,777,057)
Other income:    
Interest income 12,620 71,291
Settlement of accounts payable 535,087
Total other income 547,707 71,291
Net loss (1,667,372) (4,705,766)
Other comprehensive gain:    
Unrealized gain on debt securities 1,511
Comprehensive loss $ (1,667,372) $ (4,704,255)
Net loss per common share - basic and diluted $ (0.05) $ (0.58)
Weighted average common shares outstanding - basic and diluted 34,910,882 8,055,921

Source